December 3, 2018
Mundipharma China to sell Swiss Helsinn’s first cancer supportive care in China
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: China
September 27, 2017
Novo Nordisk’s diabetes drug in China
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.
July 21, 2017
SillaJen, Lee’s Pharmaceutical cleared for third phase testing cancer treatment Pexa-Vec
SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.
June 20, 2017
Sanovas expands in China, $75 million in capitalization
Sanovas, Inc., a Life Science technology company will establish a venture capital fund and Innovation Center at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences to advance the company’s innovations and sales in China.
April 5, 2017
Sanofi’s partner JHL Biotech accepted for clinical trial in China
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
February 23, 2017
China updates key drug list in boost for Big Pharma
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
February 16, 2017
Denovo plans on restarting DB102 trial, in China and US
Denovo Biopharma’s new clinical center in China opened last year will play a very important role in the biomarker driven DB102 trial, as the company has submitted the IND application to the China FDA.
February 6, 2017
Advanced Oncotherapy exits deal with Sinophi for its China&SE Asia proton therapy system
Advanced Oncotherapy has dropped taking legal measures against Sinophi Healthcare Limited (Sinophi), as the companies have agreed to terminate the purchase from March and October 2015.
January 24, 2017
Advanced Oncotherapy to take “appropriate action” against Sinophi Healthcare
Advanced Oncotherapy said on Tuesday it will “appropriately” deal with a UK company Sinophi Healthcare, which invests in and manages hospitals in China, because it wanted to drop purchase orders made two years ago.
December 27, 2016
Beijing buyers club? China’s cancer patients gamble on gray market
When her father’s lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly $3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.